Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 401–500 of 704
Therapeutic implications of the gastrointestinal microbiome
Kashyap, P., & Quigley, E. M. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.004 · Cited by 15
The surviving sepsis campaign: basic/translational science research priorities
Deutschman, C. S., Hellman, J., Ferrer, R., Backer, D. D., Coopersmith, C. M., Coopersmith, C. M., Backer, D. D., Antonelli, M. M., Deutschman, C. S., Evans, L., et al. (2020) · Intensive Care Medicine Experimental · doi:10.1186/s40635-020-00312-4 · Cited by 15
Cong, J., Zhang, Y., Xue, Y., Zhang, C., Xu, M., Liu, D., Zhang, R., & Zhu, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583525 · Cited by 14
The Role of Gut Microbiota in Heart Failure: When Friends Become Enemies
Cianci, R., Franza, L., Borriello, R., Pagliari, D., Gasbarrini, A., & Gambassi, G. (2022) · Biomedicines · doi:10.3390/biomedicines10112712 · Cited by 14
“It has been shown, for example, that Eggerthella lenta is implied in patients’ response to digoxin [114], and a Dutch study pointed out that the metabolism of drugs used to control HF, such as angiotensin-converting enzyme inhibitors, β-blockers, and angiotensin II-receptor blockers, varied significantly with variatio…”
MagMD: Database summarizing the metabolic action of gut microbiota to drugs
Zhou, J., Ouyang, J., Gao, Z., Qin, H., Wu, J., & Shi, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.021 · Cited by 14
“So far it has been reported over 180 drugs are regarded as substrates for gut bacterial enzymes, and can be directly transformed by microbes in vivo [5,26].”
BackgroundTan, A., Murugapiran, S. K., Mikalauskas, A., Koble, J., Kennedy, D., Hyde, F. W., Ruotti, V., Law, E., Jensen, J., Schroth, G. P., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03037-y · Cited by 13
“In particular, transcriptomic measurements of the human gut associated microbiome have been used to study microbial carbohydrate metabolism [7] and to provide functional information about intestinal diseases such as IBD [8] as well as mechanisms of drug metabolism [9].”
BackgroundJain, H., Marsool, M. D. M., Goyal, A., Sulaiman, S. A., Fatima, L., Idrees, M., Sharma, B., Borra, V., Gupta, P., Nadeem, A., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102179 · Cited by 14
Xia, K.-R., Zhang, X., Zhang, H.-Q., Su, K., Shang, E., Xiao, Q.-L., Li, W., Guo, S., Duan, J., & Liu, P. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118158 · Cited by 16
Beldie, L.-A., Dica, C.-C., Moța, M., Pirvu, B.-F., Burticală, M.-A., Mitrea, A., Clenciu, D., Efrem, I. C., Vladu, B. E., Timofticiuc, D. C. P., et al. (2024) · Nutrients · doi:10.3390/nu16234131 · Cited by 17
Clinical Microbiome Analysis by Mass Spectrometry–Based Metaproteomics
Zhang, X., Ning, Z., Mayne, J., & Figeys, D. (2025) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-071124-113819 · Cited by 17
Zhang, J., Empl, M. T., Schneider, M., Schröder, B., Stadnicka-Michalak, J., Breves, G., Steinberg, P., & Sturla, S. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.04.004 · Cited by 11
Large scale microbiome profiling in the cloud
Valdes, C., Stebliankin, V., & Narasimhan, G. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz356 · Cited by 12
Zhang, J., Zhang, J., Wang, R., & Jia, Z. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666181019145159 · Cited by 14
Ai, P., Xu, S., Yuan, Y., Xu, Z., He, X., Mo, C., Zhang, Y., Yang, X., & Xiao, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115282 · Cited by 17
“No-table examples include the Eggerthella lenta (E. lenta) -mediated inactivation of digoxin via cardiac glycoside reductases and Faecalibacterium prausnitzii (F. prausnitzii) -associated tacrolimus resistance in transplant recipients [9–11].”
Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis
Amabebe, E., Tatiparthy, M., Kammala, A. K., Richardson, L., Taylor, B. D., Sharma, S., & Menon, R. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00748-0 · Cited by 17
“Although the mechanisms and genetic basis for the microbiome-drug interactions remain largely elusive, mechanisms associated with some drugs, including acetaminophen 70 , digoxin 71 , and cyclophosphamide 72 ,havebeenunraveled.”
Impact of Gut Microbiota on Drug Metabolism and Absorption
Burke, K., & Li, Y. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00429-8 · Cited by 17
Complex influences of gut microbiome metabolism on various drug responses
Chae, S., Kim, D. J., & Cho, J. (2020) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2020.28.e3 · Cited by 14
“lenta to metabolize digoxin into dihydrodigoxin, leading to decreased exposure of the host to digoxin [14,15].”
BackgroundImpact of intestinal microbiota on metabolic toxicity and potential detoxification of amygdalin
Wen, Q., Yu, S., Wang, S., Qin, Y., Xia, Q., Wang, S., Chen, G., Shen, C., & Song, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1030516 · Cited by 18
“As an additional metabolic “organ,” intestinal microbiota is involved in the metabolism of some drugs, such as digoxin (Haiser et al., 2013), L-dopa (Jameson and Hsiao, 2019), and irinotecan (Alexander et al.”
BackgroundBioengineered human gut-on-a-chip for advancing non-clinical pharmaco-toxicology
Shin, Y. C., Than, N., Park, S. J., & Kim, H. J. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2365254 · Cited by 14
“However, this metabolic activity of E. lenta is suppressed in a high-protein diet rich in arginine [89].”
Senina, A. M., Markelova, M., Khusnutdinova, D. R., Siniagina, M., Kupriyanova, O. V., Synbulatova, G. E., Kayumov, A. R., Boulygina, E. A., & Grigoryeva, T. V. (2024) · Microorganisms · doi:10.3390/microorganisms12081712 · Cited by 15
“It regulates intestinal and systemic hormones [2], proliferation and differentiation of epithelial cells, modification and elimination of specific toxins/drugs [3,4], bone growth and development [5,6], modulation of intestinal barrier function [7,8], and sleep duration and quality [9].”
BackgroundSynbiotics in Alzheimer’s disease: mechanisms, clinical evidence, and therapeutic prospects
Lin, Y., Weng, R., Pan, H., Hou, Y., Sun, Y., & Wen, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07064-3 · Cited by 18
von Schwartzenberg, R. J., & Turnbaugh, P. J. (2015) · Cell · doi:10.1016/j.cell.2015.11.012 · Cited by 15
“Machine-learning algorithms could be more broadly applicable to pharmacology and toxicology, especially for drugs with a narrow therapeutic window, such as those used for heart failure (Haiser et al., 2013) or cancer (Wallace et al., 2010).”
BackgroundSelf-citationParkinson disease, levodopa and the gut microbiota—when microbiology meets pharmacology
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.14919 · Cited by 13
Transforming of Triptolide into Characteristic Metabolites by the Gut Microbiota
Peng, R., Ma, S., Fu, J., Han, P., Pan, L., Zhang, Z., Yu, H., & Wang, Y. (2020) · Molecules · doi:10.3390/molecules25030606 · Cited by 12
“The modification function of intestinal microorganisms can lead to the activation of these compounds (such as sulfasalazine [10]), inactivation (such as digoxin [11]), or poisoning (such as irinotecan [12]).”
BackgroundCardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance
Curini, L., & Amedei, A. (2021) · Biomedicines · doi:10.3390/biomedicines9101338 · Cited by 17
Beebe, K. D., Sampey, B. P., Watkins, S. M., Milburn, M. V., & Eckhart, A. D. (2014) · Clinical and Translational Science · doi:10.1111/cts.12131 · Cited by 14
Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?
Lu, L., Wu, Y., Zuo, L., Luο, X., & Large, P. J. (2013) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-013-1507-x · Cited by 16
“lenta was grown in the arginine-enriched media, the conversion of digoxin to dihydrodigoxin was inhibited (Haiser et al. 2013).”
BackgroundInfluentialPrinciples and Terminology for Host–Microbiome–Drug Interactions
Heirali, A., Moossavi, S., Arrieta, M., & Coburn, B. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad195 · Cited by 13
“lenta strains was described almost four decades ago [15, 22].”
BackgroundKlure, D. M., & Dearing, M. D. (2023) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiad127 · Cited by 13
Intestinal Microbiota and Vaccinations: A Systematic Review of the Literature
Loddo, F., Laganà, P., Rizzo, C. E., Calderone, S. M., Romeo, B., Venuto, R., Maisano, D., Fedele, F., Squeri, R., Nicita, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13030306 · Cited by 14
“Moreover, it facilitates the synthesis of vitamins [18], neurotransmitters [15], and many other substances with unknown targets; it supports the metabolism of bile salts [19] and allows for the elimination of exogenous toxins [20].”
Does the Human Gut Virome Contribute to Host Health or Disease?
Pavia, G., Marascio, N., Matera, G., & Quirino, A. (2023) · Viruses · doi:10.3390/v15112271 · Cited by 12
Deng, Z.-L., Pieper, D. H., Stallmach, A., Steube, A., Vital, M., Reck, M., & Wagner‐Döbler, I. (2023) · Microbiome · doi:10.1186/s40168-023-01713-9 · Cited by 12
Meds Modify Microbiome, Mediating Their Effects
Koropatkin, N. M., & Martens, E. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.022 · Cited by 11
“Likewise, the orally administered cardiac drug digoxin is modified by some gut bacteria, reducing its potency (Haiser et al., 2013).”
BackgroundMehmood, K., Moin, A., Hussain, T., Rizvi, S. M. D., Gowda, D., Shakil, S., & Kamal, M. (2021) · Folia Microbiologica · doi:10.1007/s12223-021-00926-5 · Cited by 12
“Therefore, inter-individual variation in gut bacterial flora can contribute to the altered drug response (Haiser and Turnbaugh 2013; Spanogiannopoulos et al.”
BackgroundZhong, J. W., Guo, K., Liao, Z.-L., Hu, S.-C., Du, Y., & Ji, X. (2022) · Coral Reefs · doi:10.1007/s00338-021-02200-z · Cited by 13
Carbonero, F. G. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0046 · Cited by 14
Drug Metabolism as a Community Effort
Hitchings, R., & Kelly, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.005 · Cited by 10
NNAN: Nearest Neighbor Attention Network to Predict Drug–Microbe Associations
Zhu, B., Xu, Y., Zhao, P., Yiu, S., Yu, H., & Shi, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.846915 · Cited by 11
Bringing pharmacomicrobiomics to the clinic through well‐designed studies
Steiner, H. E., Patterson, H. K., Giles, J. B., & Karnes, J. H. (2022) · Clinical and Translational Science · doi:10.1111/cts.13381 · Cited by 12
Identification of age-associated microbial changes via long-read 16S sequencing
Toh, K. Y., Toh, T. S., Chua, K. P., Rajakumar, P. D., Lee, J. W. J., & Chong, C. W. (2024) · Gut Pathogens · doi:10.1186/s13099-024-00650-8 · Cited by 10
“This gut bacterium is also involved in the inactivation of the cardiac drug digoxin [36].”
BackgroundPidgeon, R., Giurleo, A., Dridi, L., & Castagner, B. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00849-w · Cited by 13
“The transcription of gut bacterial xenobiotic metabolizing enzymes is oftenaninducibleprocesstriggereduponexposuretotheirsubstrates 58,59 .”
Cong, J., Zhang, C., Zhou, S., Zhu, J., & Liang, C. (2022) · Cancers · doi:10.3390/cancers14153599 · Cited by 11
“The pharmacological effects of drugs, such as activation [50], inactivation [51], toxification [52], and other compound modifications, are strongly influenced by intestinal microbiota.”
BackgroundNovel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism
Tan, J., Fu, B., Zhao, X., & Ye, L. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00874-0 · Cited by 12
“1 The main modes of drug metabolism by the gut microbiota can inactivate the drug as this microbe encodes the cardiac glycoside reductase manipulator, which is responsible for the inactivation of digoxin metabolism [22, 23].”
Gut Microbiome of Patients With Breast Cancer in Vietnam
Nguyen, S. M., Tran, H. T.-T., Long, J., Shrubsole, M. J., Cai, H., Yang, Y., Nguyen, L. M., Nguyen, G. H., Nguyen, C. V., Ta, T. V., et al. (2024) · JCO Global Oncology · doi:10.1200/go.23.00234 · Cited by 15
Microbiology and Ecology Are Vitally Important to Premedical Curricula
Smith, V. H., Rubinstein, R., Park, S., Kelly, L., & Klepac‐Ceraj, V. (2015) · Evolution Medicine and Public Health · doi:10.1093/emph/eov014 · Cited by 15
“For example, Clostridium sporogenes plays an important role in reductive metabolism of the anti-seizure drug zonisamide [140], while Eggerthella lenta can convert the cardiac glycoside digoxin into an inactive form [138, 141, 142].”
BackgroundKumar, K., Dhoke, G. V., Sharma, A. K., Jaiswal, S. K., & Sharma, V. K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28396 · Cited by 10
“One of the most prominent and interesting examples on the role of gut bacteria in the metabolism of a drug molecule is digoxin, which is a cardiac glycoside mainly used for the treatment of multiple heart failures.(13) In different populations, a differential therapeutic effect of this drug has been observed due to it…”
BackgroundThe Microbiome Factor in Drug Discovery and Development
Nuzzo, A., & Brown, J. R. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00333 · Cited by 11
New insights into the microbiome in kidney transplantation
Kim, J. S., Sze, C., Barbar, T., & Lee, J. R. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000921 · Cited by 11
Special issue on the human microbiome: from symbiosis to therapy
Sharma, A., & Im, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00488-5 · Cited by 10
Schmitz, M. A., Dimonaco, N. J., Clavel, T., & Hitch, T. C. A. (2025) · Nature Communications · doi:10.1038/s41467-025-58442-w · Cited by 10
“Microbiome analysis has most often focused on the study of taxonomic groups, although it is the functionality of these taxa that is of interest 1,2 .”
Liu, L., Wang, H., Minichino, A., Xiao, R., Du, Y., Wang, L. Y., He, D., Guo, S., Mo, X., Xiang, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03345-x · Cited by 10
Decipher enzymes from human microbiota for drug discovery and development
Beliaeva, M. A., Wilmanns, M., & Zimmermann, M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102567 · Cited by 10
Actualité du microbiote intestinal
Bourlioux, P. (2013) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2013.09.001 · Cited by 14
The Modulation of Drug Efficacy and Toxicity by the Gut Microbiome
Wilson, I. D., & Nicholson, J. K. (2014) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6539-2_15 · Cited by 10
Han, W., & Ye, Y. (2018) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813279827_0022 · Cited by 9
Nowicka, A., Tomczak, H., Szałek, E., Karbownik, A., & Gil, L. (2025) · Biomedicines · doi:10.3390/biomedicines13071761 · Cited by 9
Orjichukwu, C. K., Orjichukwu, R. O., Akpunonu, P. K., Ugwu, P. C. O., & Nnabuife, S. G. (2025) · Medical Sciences · doi:10.3390/medsci13040302 · Cited by 10
New Personalized Medicine Model for Medication Management
Alagiakrishnan, K., Halverson, T., Olivares, D. V. F., & Sadowski, C. A. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16040182 · Cited by 10
The microbiome regulates host metabolic health and diseases through microbial enzymes
Ding, Y., Zhang, Z., Wang, K., & Jiang, C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01195-8 · Cited by 16
Naik, A., & Misra, S. K. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02736 · Cited by 10
Adaptive and powerful microbiome multivariate association analysis via feature selection
Banerjee, K., Chen, J., & Zhan, X. (2022) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab120 · Cited by 10
“On the other hand, strain level associations with the metabolism of drugs in human have been reported (40).”
Multi-omic analysis of host-microbial interactions central to the gut-brain axis
Simpson, J. B., & Redinbo, M. R. (2022) · Molecular Omics · doi:10.1039/d2mo00205a · Cited by 9
Framework for exploring the sensory repertoire of the human gut microbiota
Ross, P. A., Xu, W., Jalomo-Khayrova, E., Bange, G., Gumerov, V. M., Bradley, P. H., Sourjik, V., & Zhulin, I. B. (2024) · mBio · doi:10.1128/mbio.01039-24 · Cited by 7
Couvillion, S., Agrawal, N., Colby, S., Brandvold, K. R., & Metz, T. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00388 · Cited by 10
“lenta where the mere presence of the microbe in the gut was not found to correlate with levels of drug inactivation (Saha et al., 1983; Haiser et al., 2013).”
BackgroundBhushan, B., Singh, B. P., Kumari, M., Mishra, V., Saini, K., & Singh, D. (2019) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-04675-0_7 · Cited by 9
The secret social lives of African crested rats, Lophiomys imhausi
Weinstein, S. B., Malanga, K. N., Agwanda, B. R., Maldonado, J. E., & Dearing, M. D. (2020) · Journal of Mammalogy · doi:10.1093/jmammal/gyaa127 · Cited by 10
Drug Response Diversity: A Hidden Bacterium?
Hannachi, N., & Camoin‐Jau, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050345 · Cited by 9
Bess, E. N., Bisanz, J. E., Spanogiannopoulos, P., Ang, Q. Y., Bustion, A. E., Kitamura, S., Alba, D., Wolan, D. W., Koliwad, S. K., & Turnbaugh, P. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/357640 · Cited by 8
“for linking genomic loci to metabolic activities (4, 29), even in genetically intractable microorganisms.”
BackgroundSelf-citationPervasive selective sweeps across human gut microbiomesPreprint
Wolff, R., & Garud, N. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.22.573162 · Cited by 8
“These evolutionary dynamics can have functional consequences for the host, as microbial genetic variants are associated with metabolic capacity, disease susceptibility, and many other host phenotypes [8, 9, 10, 11].”
Association between the Maternal Gut Microbiome and Macrosomia
Zhong, Z., An, R., Ma, S., Zhang, N., Zhang, X., Chen, L., Wu, X., Lin, H., Xiang, T., Tan, H., et al. (2024) · Biology · doi:10.3390/biology13080570 · Cited by 9
“The gut microbiome can be regarded as a “micro-bial organ” that regulates food digestion, energy utilization [11], neurotransmitters [12], drug metabolism [13], and host metabolism and its function is closely related to host physiology and pathophysiology [14].”
BackgroundPhotoaffinity probe-enabled discovery of sennoside A reductase in Bifidobacterium pseudocatenulatum
Xu, Y., Lv, S., Li, X., Zhai, C., Shi, Y., Li, X., Feng, Z., Luo, G., Wang, Y., & Gao, X. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101108 · Cited by 8
“Traditional methods for identifying drug metabolic enzymes include genomic analysis, transcriptomics analysis [11], proteomics analysis [12], mining based on homologous enzymes [13], and so on [14].”
McCoubrey, L. E., Shen, C., Mwasambu, S., Favaron, A., Sangfuang, N., Thomaidou, S., Orlu, M., Globisch, D., & Basit, A. W. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106922 · Cited by 8
“One example was published by Haiser et al, wherein the bacterial metabolism of digoxin was shown to be inhibited by arginine (Haiser et al., 2013).”
Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies
Alvarado, S. J., López-Tenorio, I. I., Santos, J. B.-D. L., Bello-Vega, D. C., Roldán, F., Amedei, A., Berrios-Bárcenas, E. A., & Aguirre‐García, M. M. (2025) · Biomedicines · doi:10.3390/biomedicines13010144 · Cited by 11
Anwar, F., Al-Abbasi, F. A., Al-Bar, O. A., Verma, A., & Kumar, V. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01593-x · Cited by 8
“Dihy-drodigoxin, a reduced metabolite of parent drug digoxin, results in poor efficacy in some patients by actinobacterium, Eggerthella lenta (Haiser et al. 2013; Kyaw et al. 2024).”
Pharmacomicrobiomics informs clinical pharmacogenomics
Κάτσιλα, Θ., Balasopoulou, A., Tsagaraki, I., & Patrinos, G. P. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0027 · Cited by 7
Correlation between postmortem microbial signatures and substance abuse disorders
Javan, G. T., Wells, T., Allen, J., Visoná, S. D., Moretti, M., Tipton, C. D., Scott, L., & Finley, S. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274401 · Cited by 11
“Since then, significant work has gone into characterizing the gene operon, now known as cgr (cardiac glycoside reductase), and its role in cardiac drug inactivation [48].”
BackgroundAlteration of Community Metabolism by Prebiotics and Medicinal Herbs
Peterson, C. T., Pérez‐Santiago, J., Iablokov, S. N., Rodionov, D. A., & Peterson, S. N. (2023) · Microorganisms · doi:10.3390/microorganisms11040868 · Cited by 7
“The clinical implications of this result are vague, but an increasing number of studies of member species indicate their broad metabolic capacity to biotransform molecules, including medications such as levadopa [36] and the cardiac drug digoxin [37].”
BackgroundYang, K., Xu, M., & Zhu, J. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00806 · Cited by 8
Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020
Aziz, R. K., Rizkallah, M. R., Saad, R., & ElRakaiby, M. T. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0205 · Cited by 9
“…microbes, to eliminate specific microbes that aggravate adverse effects of chemotherapeutic agents, or as a supportive therapy with some drugs with narrow therapeutic index (e.g., digoxin) to remove bacteria that render it inefficient (e.g., Cgr-encoding Eggerthella lenta ; Haiser et al., 2013).”
The human intestinal bacterium Eggerthella lenta influences gut metabolomes in gnotobiotic mice
Viehof, A., Haange, S., Streidl, T., Schubert, K. A., Engelmann, B., Haller, D., Rolle-Kampczyk, U. E., von Bergen�, M., & Clavel, T. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.65 · Cited by 11
Transformative Forces: The Role of Gut Microbiota in Processing Environmental Pollutants
Lv, M., Liu, Y., Wang, M., Song, X., Hu, Y., Gao, J., Chen, L., Liu, A., Liu, J., Liu, R., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c01928 · Cited by 8
Gnatzy, L., Ismailos, G., Vertzoni, M., & Reppas, C. I. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106510 · Cited by 8
Rodents consuming the same toxic diet harbor a unique functional core microbiome
Stapleton, T. E., Lindsey, L. M., Sundar, H., & Dearing, M. D. (2024) · Animal Microbiome · doi:10.1186/s42523-024-00330-7 · Cited by 8
“Notably, several microbes that belong to Eggerthellaceae are capable of degrading PSCs [7, 9, 11, 43, 72].”
BackgroundTowards precision medicine: Leading with big data and multidisciplinary collaboration
Zhu, T., Yang, M., Wang, Y., Xu, J., & Dai, H. (2024) · Precision medication. · doi:10.1016/j.prmedi.2024.10.003 · Cited by 7
Becker, H. E. F., Penders, J., & Jonkers, D. M. A. E. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.050 · Cited by 6
Tian, X., Wu, Y., Duan, C., Zhou, X., Li, Y., Zheng, J., Lai, W., Zhang, S., Cao, L., & Zhong, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1013973 · Cited by 7
“Similarly, the orally administered cardiac drug digoxin is changed by certain gut bacteria, reducing its effectiveness (Haiser et al., 2013).”
BackgroundBiotransformation research advances – 2022 year in review
Khojasteh, S. C., Argikar, U. A., Cheruzel, L., Cho, S., Crouch, R. D., Dhaware, D., Heck, C. J. S., Johnson, K. M., Kalgutkar, A. S. S., King, L. M., et al. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2262161 · Cited by 6
“A reduction of C ¼ C bonds by gut microbiota has been previously reported with digoxin and delobuvir (Haiser et al. 2013; McCabe et al. 2015).”
BackgroundLabossiere, A., Ramsey, M. M., Merritt, J. L., & Kreth, J. (2023) · mBio · doi:10.1128/mbio.01342-23 · Cited by 10
“However, further research in this area is necessary; for example, we know that depending on the pharmaceutical drug and the composition of a person’s gut, it can sometimes lead to the medication becoming less efficacious (144, 145).”
BackgroundMicrobial Features Linked to Medication Strategies in Cardiometabolic Disease Management
Shearer, J., Shah, S., Shen‐Tu, G., Schlicht, K., Laudes, M., & Mu, C. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00261 · Cited by 8
Epithelial delamination is protective during pharmaceutical-induced enteropathy
Espenschied, S. T., Cronan, M. R., Matty, M. A., Mueller, O., Redinbo, M. R., Tobin, D. M., & Rawls, J. F. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902596116 · Cited by 7
“Previous studies have established that intestinal microbiota are able to metabolize and transform some xenobiotics, including pharmaceuticals (17, 18, 35, 36).”
BackgroundThe impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease
Jacob, J. S., Ahmed, A., & Cholankeril, G. T. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000759 · Cited by 6
Bridging the Gap between Analytical and Microbial Sciences in Microbiome Research
Quinn, R. A., Hagiwara, K. A., Liu, K., Goudarzi, M., Pathmasiri, W., Sumner, L. W., & Metz, T. (2021) · mSystems · doi:10.1128/msystems.00585-21 · Cited by 8
A diet-dependent enzyme from the human gut microbiome promotes Th17 cell accumulation and colitisPreprint
Alexander, M., Ang, Q. Y., Nayak, R. R., Bustion, A. E., Upadhyay, V., Pollard, K. S., & Turnbaugh, P. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/766899 · Cited by 8
“12 Cgr2 has been previously studied for its role in reducing the heart medication digoxin into 1 a less active by-product, dihydrodigoxin (12).”
BackgroundInfluentialSelf-citationNew chemicals fuel the evolution of microbial biodegradation
Wackett, L. P. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00207-24 · Cited by 9
An introduction to human microbiome
Das, B. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.026 · Cited by 7
Kolodnitsky, A. S., Ионов, Н. С., Rudik, A. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2023) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2023.2214375 · Cited by 5
Personalized nutrition, personalized medicine, and microbiome therapeutics
Chauhan, N. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00017-3 · Cited by 13
Varshney, N., Saini, V., & Jha, H. C. (2024) · Springer eBooks · doi:10.1007/978-981-97-1912-9_6 · Cited by 5
Stephens, C. M., Lucena, M. I., & Andrade, R. J. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_23 · Cited by 5
Gut Microbiota and Specific Response to Diet
Amamou, A., O’Mahony, C., Llopis-Grimalt, M. A., Cruzel, G., Caplice, N. M., Herisson, F. M., & Ghosh, S. (2023) · Endocrinology · doi:10.1007/978-3-031-08115-6_17-1 · Cited by 7
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.